CFO yields 1.33% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, CFO + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CFO + JNJ for your $10,000?
The VictoryShares US 500 Enhanced Volatility Wtd ETF seeks to provide investment results that track the performance of the Nasdaq Victory US Large Cap 500 Long/Cash Volatility Weighted Index (the Long/Cash Index) before fees and expenses. Volatility Weighting Methodology Combines fundamental criteria and volatility weighting in an effort to outperform traditional cap-weighted indexing strategies. About the Index The Long/Cash Index tactically reduces its exposure to the equity markets during periods of significant market declines and reinvests when market prices have further declined or rebounded. The Nasdaq Victory US Large Cap 500 Long/Cash Volatility Weighted Index is based on the month-end price of the Nasdaq Victory US Large Cap 500 Volatility Weighted Index (the “Reference Index”). The exit and reinvestment methodology of the Long/Cash Index is based on the month-end value of the Reference Index relative to its All-Time Highest Daily Closing Value (“AHDCV”). AHDCV is the highest daily closing price the Reference Index has achieved since its inception date.
Full CFO Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.